Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

Exclusion Criteria

• •Prior treatment with any chemotherapy, anti-HER2 therapy, radiotherapy, or endocrine therapy, etc
• •Locally advanced (cT4/cN3) or bilateral breast cancer
• •Patients with known allergies to any active ingredients or excipients of investigational medicinal product
• •Other malignancy diagnosed within 5 years prior to enrollment, excluding cervical carcinoma in situ and cured melanoma skin cancer
• •Left ventricular ejection fraction (LVEF) \< 55%
• •Uncontrolled hypertension (systolic \> 150 mm Hg and/or diastolic \> 100 mm Hg)
• •Severely cardiovascular disease
• •Current known infection with HIV, hepatitis B virus, or hepatitis C virus
• •Patients with pulmonary disease requiring continuous oxygen therapy, previous history of bleeding diathesis or patient is currently receiving anti-coagulant therapy, or immunosuppressive agent
• •Major surgical procedure or significant traumatic injury
• •Patient has other concurrent severe and/or uncontrolled medical conditions.
• •Concurrent participation in other interventional clinical trial
• •History of receiving any investigational treatment within 28 days prior to randomization
• •Pregnant or breast-feeding women or patients not willing to apply highly effective contraception as defined in the protocol
• •Inability to lie flat or presence of psychiatric disorders such as claustrophobia